This study was attempted to investigate on renal effect of (±)6-chloro-7,8-dihydroxy-1-phenyl 2,3,4,5-tetrahydro-1H-3 benzazepine (SKF 81297), dopamine D₁ receptor agonist, in dog. SKF 81297, when given intravenously, produced diuretic action along with the increases of renal plasma flow (RPF), glomerular filtration rate (GFR), amounts of Na^+ and K^+ excreted into urine (E_(Na), E_K) and osmolar clearance (C_(osm)). It also decreased the reabsorption rates of Na^+ and K^+ in renal tubule (R_(Na), R_K) and free water clearance (C_(H2O)), whereas ratios of K^+ agonist Na^+ in urine and filtration fraction (FF) was not changed. SKF 81297, when administered into a renal artery, elicited diuresis both in experimental kidney given the SKF 81297 and control kidney not given, while the effect was more remarkable in experimental kidney than those exhibited in control kidney. SKF 81297 given into carotid artery also exhibited diuresis, the potency at this time, compared to those induced by intravenous SKF 81297, was magnusgreat. Above results suggest that SKF 81297 produces diuresis by both indirect action through changes of central function and direct action being induced in kidney. Central diuretic action is mediated by improvement of renal hemodynamics, but direct action by inhibition of electrolytes reabsorption in renal tubule.